




Pre-examination Process (for labs) Validation of test - II

Francesco Fiorentino

Lab Director
GENOMA - Molecular Genetics Laboratory
Rome - Italy
fiorentino@laboratoriegenoma.it

MUTATION ANALYSIS



MUTATION ANALYSIS

**Indirect
Diagnosis**



Indications for indirect diagnosis

- **Direct mutation testing is not possible**
 - The mutation is unknown
 - The mutation is a large deletion/insertion with unknown breakpoints
- **Direct mutation testing is not efficient**
 - The gene region to be amplified is refractory to PCR (e.g. GC-rich)
 - Presence of a pseudogene
- **Genes with a wide spectrum of mutations**
 - indirect diagnosis as a general protocol for different couples
- **Preimplantation HLA matching**
 - flexible indirect HLA typing protocol applicable to a wide spectrum of possible HLA genotypes
- **Exclusion testing**
 - e.g. Huntington disease



Indirect diagnosis: Pros / Cons

Advantages:


- No mutation analysis
 - same protocol useful for many couples
- Useful for rare disorders with private mutations


Disadvantages:

- Applicable to informative couples with family history
 - At least two affected family members needed
- Not applicable in cases of *de novo* mutation and no previous pregnancies



Principle of indirect diagnosis





Genetic Markers

- Single nucleotide polymorphisms (SNPs)
 - single base change in genomic DNA `TGCATTGCGTAGGC`
 - one per every 500 - 1000 base pairs `TGCATTCCGTTAGGC`
 - less informative than microsatellite markers
 - low mutation rate* ($\approx 10^{-9}$)
- Short Tandem Repeats (STRs) or Microsatellites
 - 1 every few kb, high degree of heterozygosity
 - mutation rate* $\leq 10^{-3}$
 - Types:
 - di- (CA)_n,
 - tri- (CAG)_n,
 - tetra- (GATA)_n,
 - Penta- (AAAA)_n nucleotide repeats
 - Minisatellites (VNTR - variable number tandem repeats)
 - 1 every few kb
 - mutation rate* $\leq 10^{-1}$

Microsatellites Markers

microsatellite

(ca)_n

the repeat region is variable between samples while the flanking regions where PCR primers bind are constant

gacctaatc ca ca taccgtta Allele 2

gacctaatc ca ca ca ca ca taccgtta Allele 5


Alleles distinguishable by PCR product length

Homozygote = both alleles are the same length

Heterozygote = alleles differ and can be resolved from one another

Microsatellite Characteristics

Stutter Peaks: Di-nucleotide vs Tetra-nucleotide Repeats



Microsatellite Marker Types

Dinucleotide Repeat Markers

E.g.: (CA)(CA)(CA)...(CA)_n




- Abundant coverage
- Characteristic stutter patterns
 - Interpretation can be complex



Microsatellite Marker Types

Tetranucleotide Repeat Markers

E.g.: (TCTA)(TCTA)...(TCTA)_n



- Well characterised
- Discrete allele peaks
- Low, predictable and measurable stutter peaks
 - Easier interpretation




How to build the haplotypes?

- Selection of the STR markers linked to the disease causing gene




The choice of linked STR markers



How to build the haplotypes?

- Selection of the STR markers linked to the disease causing gene
- Evaluation of the informativity of the markers:
- Selection of the informative markers
 - Preferably fully informative (i.e., 4 different alleles, father a/b and mother c/d)
- Identification of the alleles associated with the mutation/disease






How to build the haplotypes?


- Selection of the STR markers linked to the disease causing gene
- Evaluation of the informativity of the markers:
- Selection of the informative markers
 - Preferably fully informative (i.e., 4 different alleles, father a/b and mother c/d)
- Identification of the alleles associated with mutation/disease
- Determination of the haplotypes



DETERMINING HAPLOTYPES FOR LINKAGE ANALYSIS



DETERMINING HAPLOTYPES FOR LINKAGE ANALYSIS



Linkage-based PGD protocols: general guidelines

- Type of markers:
 - STRs, preferably tetra-nucleotide repeat (di-nucleotide repeat are also acceptable)
- Location of STR markers:
 - preferentially intragenic or extragenic, very closed to the gene (max 1 Mb of distance) to reduce the risk of recombination events
- Heterozygosity of STR markers
 - High (>0.8) to improve informativity of the markers
- No. of STR markers
 - Preferably 4, 2 upstream and 2 downstream
- Size of the alleles
 - Small product size (preferably < 250 bp) to improve PCR efficiency
- Number of family members
 - At least two generations or affected family members




Indirect Diagnosis

Exclusion Testing



Exclusion of HD using linkage




Indirect Diagnosis

WGA
+
Haplotyping




Whole Genome Amplification (WGA)

- Universal first amplification step
- WGA product analysis in conventional facilities
- No requirement for development of special single cell/mutation detection tests



Multiple Displacement Amplification

- Isothermal, no cycling involved (incubation at 30°C)
- Random priming using exonuclease resistant modified random hexamers
- Polymerase makes strand and displaces other strand, e.g. F29 polymerase
- 104-106-fold amplification
- Obtaining µg of DNA



Spits et al., 2006, Nature Protocols, Vol 1(4): 1965-1970



MDA and PGD

- Use for haplotyping in PGD for monogenic disease (PGH)
 - High ADO rate, many markers have to be included in the protocol
- Use for array-CGH in PGS
- A combination of both



MUTATION ANALYSIS

Direct + Indirect
Diagnosis



The use of STR markers in PGD procedure

- ☞ Represents a diagnostic tool for indirect mutation analysis, providing an additional confirmation of the results obtained with the direct genotyping procedure
- ☞ provides a control of misdiagnosis due to undetected ADO
- ☞ provides an additional control for contamination with exogenous DNA
- ☞ Provides information on embryo's chromosomes copy number
- ☞ PGD protocols for SGD are not appropriate for clinical practice without including a set of linked STR markers




Allele drop-out

- ☞ Allele drop-out (ADO) is defined as the non-amplification of one allele when performing PCR at the single cell level.
- ☞ This phenomenon can only be demonstrated in heterozygote cells, which show a homozygous pattern when ADO has occurred
- ☞ ADO occurs in all cell types, e.g. blastomeres, lymphocytes, buccal cells and fibroblasts.
- ☞ An undetected ADO event leads to misdiagnosis



Avoidance of misdiagnosis due to ADO





STR markers: Other application in PGD


Preimplantation HLA Matching



Preimplantation HLA Matching by STR haplotyping




Affected child HLA identical embryo



Informativity testing for preimplantation HLA matching

| MARKER | MOTHER | | FATHER | | CHILD | |
|-----------|--------|-----|--------|-----|-------|-----|
| | 107 | 114 | 105 | 114 | 105 | 114 |
| TNF1 | 107 | 114 | 105 | 114 | 105 | 114 |
| D6S510 | 155 | 140 | 151 | 148 | 151 | 140 |
| D6S426 | 120 | 128 | 120 | 124 | 120 | 128 |
| MICA | 168 | 171 | 171 | 168 | 171 | 171 |
| D6S273 | 142 | 144 | 136 | 142 | 136 | 144 |
| D6S276 | 218 | 220 | 216 | 211 | 216 | 220 |
| LHI | 144 | 146 | 141 | 144 | 141 | 146 |
| DQ CAR II | 131 | 118 | 130 | 123 | 130 | 118 |
| DRA CA | 130 | 137 | 130 | 139 | 130 | 137 |
| MOG CA | 215 | 206 | 225 | 206 | 225 | 206 |
| HLA BC CA | 117 | 129 | 120 | 132 | 120 | 129 |
| D6S265 | 110 | 114 | 120 | 116 | 120 | 114 |
| D6S291 | 156 | 160 | 158 | 158 | 158 | 160 |
| TNF2 | 111 | 111 | 113 | 111 | 113 | 111 |
| 82-1 | 111 | 111 | 104 | 111 | 104 | 111 |
| GS1152 | 145 | 145 | 147 | 147 | 147 | 145 |
| D3A | 200 | 202 | 202 | 202 | 202 | 202 |
| RING3 CA | 126 | 124 | 124 | 126 | 124 | 124 |
| 62 | 156 | 163 | 156 | 163 | 156 | 163 |
| D6S439 | 120 | 122 | 120 | 122 | 120 | 122 |
| MIB | 177 | 177 | 172 | 177 | 172 | 177 |
| D6S105 | 141 | 141 | 139 | 153 | 139 | 141 |




The use of STR markers in HLA matching procedure

- ☛ The same strategy can be used for different cases (and allele combinations)
- ☛ STRs provide an additional control for contamination with exogenous DNA
- ☛ The whole HLA complex can be covered, allowing the detection of recombination events between HLA genes.



Avoidance of misdiagnosis due to recombination




STR markers: Other application in PGD

Detection of chromosomal Aneuploidies



Aneuploidy Detection by using STR markers:




AMA
RIF
RM

Chromosomes:
13, 14, 15, 16, 18,
21, 22, X, Y


gacctaac ca ca taccgta
gacctaac ca ca ca ca taccgta
gacctaac ca ca ca ca ca taccgta

Allele 1
Allele 2
Allele 3


Alleles are distinguishable by PCR product length



Embryo with trisomy 21




Aneuploidy Detection by using STR markers





STR markers: Other application in PGD


Detection of unbalanced chromosomal translocations





Segregation of Robertsonian Translocations














- ### STR-based PGD for translocations: advantages
- Easy procedure and data interpretation
 - Amenable to automation
 - Rapid procedure (<12 h)(4-6 h for 1PB testing)
 - Cell fixation (PBs or blastomeres) is not necessary
 - Solve suboptimal fixation problems, easier procedure for transport PGD
 - Overcome to several technical limitation of FISH procedure:
 - Overlapping signals, split signals, lack of signals, cross-hybridization, polymorphisms, limited availability of the probes, combination of colours
 - Possibility to perform combined testing
 - e.g. Translocation + PGS; Translocation + SGD with or w/o PGS
 - Post-hybridization wash and re-probing are not necessary for combined testing
 - UPD can be detected
 - Lower error rate
 - Low expensive
 - A DNA fingerprint is achievable from each embryos
 - Identification of embryos that have implanted
- 

- ### STR-based PGD for translocations: disadvantages
- **Affected by contamination**
 - **Affected by ADO – Preferential Amplification**
 - **Recombination risk in cases of 1PB testing**
- 

Future vision: unique protocol for PGD



Pre-examination Process (for labs)

Validation of the PGD Protocol



Developing a PGD protocol

- ☞ Confirmatory testing of the mutation(s)
- ☞ Choice of the PGD strategy (direct mutation diagnosis, linkage)
- ☞ Informativity testing for linked/un-linked STR markers
- ☞ Test multiplex PCR: combination of primers, etc.
- ☞ Application to the single cell level (i.e. single lymphocytes, fibroblast, buccal cells, etc.)
- ☞ Amplification efficiency, contamination and ADO rates in heterozygous samples.
- ☞ Test on spare blastomeres (depending on availability)
- ☞ Ready for PGD



Preliminary PGD work-up: parameters to be evaluated

- Pre-clinical tests on single cells (lymphocytes, fibroblasts, amniocytes, buccal cells, etc.)
 - At least 50 cells in total
- Amplification efficiency > 90 % should be aimed
 - Lower efficiency coincides with higher ADO
- ADO rates should be as low as possible (preferably <10%)
 - ADO is mostly influenced by PCR method (conventional vs. fluorescent)
- The contamination rate should be less than 5% (preferably zero)
 - At least 50 cell wash blanks

ESHRE PGD Consortium guidelines, Hum Reprod. 2005 Jan;20(1):35-48



One-cell versus two-cells biopsy

- **Doubts and discussion about one vs two-cell biopsy**
 - Risk of misdiagnosis (e.g. autosomal dominant disorders)
 - Claims that higher implantation rate is achieved after one-cell biopsy
- **Randomized control trial** (Goossens V. et al., Hum Reprod 2007)
 - Removal of two blastomeres significantly decreases the likelihood of blastocyst formation
 - one-cell biopsy results in a significantly lower diagnostic efficiency
 - live birth delivery rates were not statistically different for one- and two-cell biopsy
- **RECOMMENDATION: diagnosis of only 1 cell requires a robust PGD protocol**